Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 0.69 |
| ▸ | HDAC4 | P56524 | 12/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.69 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.69 |
| ▸ | HDAC7 | Q8WUI4 | 11/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.69 |
| ▸ | HDAC10 | Q969S8 | 11/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 11/20 | 0.69 |
| ▸ | HDAC9 | Q9UKV0 | 11/20 | 0.69 |
| ▸ | HDAC5 | Q9UQL6 | 11/20 | 0.69 |
| ▸ | HDAC11 | Q96DB2 | 10/20 | 0.69 |
| ▸ | TOP2A | P11388 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1521161 | 1.00 | HDAC1 (0.69) | HDAC1HDAC4HDAC6HDAC3HDAC7 | |
| SCHEMBL13465162 | 0.88 | HDAC1 (0.70) | HDAC1HDAC4HDAC6HDAC3HDAC7 | |
| SCHEMBL1521164 | 0.88 | HDAC1 (0.70) | HDAC1HDAC4HDAC6HDAC3HDAC7 | |
| SCHEMBL1521160 | 0.88 | HDAC1 (0.70) | HDAC1HDAC4HDAC6HDAC3HDAC7 | |
| SCHEMBL1520819 | 0.84 | HDAC1 (0.72) | HDAC1HDAC4HDAC6HDAC3HDAC7 | |
| SCHEMBL1520815 | 0.84 | HDAC1 (0.72) | HDAC1HDAC4HDAC6HDAC3HDAC7 | |
| SCHEMBL13859920 | 0.84 | HDAC1 (0.72) | HDAC1HDAC4HDAC6HDAC3HDAC7 | |
| SCHEMBL1520912 | 0.84 | HDAC1 (0.65) | HDAC1HDAC4HDAC6HDAC3HDAC7 | |
| SCHEMBL1520908 | 0.84 | HDAC1 (0.65) | HDAC1HDAC4HDAC6HDAC3HDAC7 | |
| SCHEMBL12395351 | 0.83 | HDAC1 (0.71) | HDAC1HDAC4HDAC6HDAC3HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160015693-A1 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR | AGENCY SCIENCE TECH & RES (SG) | 2016-01-21 | — | — | US | disclosed |
| US-8969313-B2 | Methods and compounds for preventing and treating a tumour | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-03-03 | — | — | US | disclosed |
| US-20110053882-A1 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2011-03-03 | — | — | US | disclosed |
| EP-2217240-A1 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR | Agency for Science, Technology And Research (SG) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009058102-A1 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053882-A1 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR | HDAC1, CCAR2, HDAC11 | HDAC1 1/4885HDAC4 24/4885HDAC6 25/4885 |
| US-20160015693-A1 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR | HDAC1, HDAC11, CCAR2 | HDAC1 1/4885HDAC4 22/4885HDAC6 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.